Orchestra BioMed Hldgs Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)
Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data
Orchestra BioMed Hldgs Analyst Ratings
Buy Rating for Orchestra BioMed Holdings: An Optimistic Outlook on BACKBEAT and Virtue SAB Studies' Potential Impact and Future Developments
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC)
Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Holdings (OBIO) Gets a Buy From LifeSci Capital
LifeSci Capital Sticks to Their Buy Rating for Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), Anavex Life Sciences (AVXL) and Recursion Pharmaceuticals (RXRX)
Orchestra BioMed Holdings (OBIO) Gets a Buy From Chardan Capital
LifeSci Capital Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Chardan Capital Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Hldgs Analyst Ratings
Piper Sandler Initiates Coverage On Orchestra BioMed Hldgs With Overweight Rating, Announces Price Target of $15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF) and Orchestra BioMed Holdings (OBIO)
No Data